DelveInsight is a healthcare-focused market research and business consulting firm serving pharma and biotech clients. It provides market intelligence, custom research, and advisory services to support commercial and strategic decisions.
New AI platforms are emerging to address rare disease diagnosis and epidemiology, as global costs reach up to $8.6 trillion annually affecting 300 million patients worldwide across more than 7,000 distinct conditions.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
